Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Julie A. Di Paolo"'
Autor:
Christopher W. Pohlmeyer, Ching Shang, Pei Han, Zhi-Hua Cui, Randall M. Jones, Astrid S. Clarke, Bernard P. Murray, David A. Lopez, David W. Newstrom, M. David Inzunza, Franziska G. Matzkies, Kevin S. Currie, Julie A. Di Paolo
Publikováno v:
BMC Rheumatology, Vol 5, Iss 1, Pp 1-13 (2021)
Abstract Background B cells are critical mediators of systemic lupus erythematosus (SLE) and lupus nephritis (LN), and antinuclear antibodies can be found in the serum of approximately 98% of patients with SLE. Spleen tyrosine kinase (SYK) is a nonre
Externí odkaz:
https://doaj.org/article/1045f0e3e1234e489fba36f11c62f5d1
Autor:
Julie A Di Paolo, Amy Meng, Bernard Murray, Paqui G. Través, Federico Campigotto, René Galien
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveJanus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofa
Autor:
Deepa Hammaker, Grant R. Budas, Julie A. Di Paolo, Gyrid Nygaard, Gary S. Firestein, Igor Mikaelian, Gregory T. Notte, Vivian Barry, David L. Boyle
Publikováno v:
Biochemical Pharmacology. 151:282-290
Despite improved therapy, rheumatoid arthritis (RA) remains an unmet medical need. Previous efforts to validate therapeutic targets in the mitogen-activated protein kinase (MAPK) family have had minimal success. Therefore, we evaluated the potential
Autor:
Shringi Sharma, Michelle Robeson, Julie A. Di Paolo, Srini Ramanathan, Lixin Shao, Feng Jin, Brian P. Kearney
Publikováno v:
Clinical Drug Investigation
Background and Objectives Entospletinib is a selective, reversible, adenosine triphosphate-competitive small-molecule spleen tyrosine kinase (SYK) inhibitor that blocks B cell receptor-mediated signaling and proliferation in B lymphocytes. This study
Autor:
Wei Jia, Victor L. Perez, Daniel R. Saban, Hsuan Su, Nancy J. Reyes, Benny J. Chen, Diana M. Cardona, Julie A. Di Paolo, Jonathan C. Poe, Nelson J. Chao, John S. Sundy, Ji Yun Kim, Stefanie Sarantopoulos, Adela R. Cardones
Publikováno v:
JCI Insight. 3
Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletin
Autor:
Anita Reddy, Susan O'Brien, Paul M. Barr, Julie A. Di Paolo, Jing Hu, Daniel Reif Greenwald, Stephen E. Spurgeon, Hank Lee, Michael J. Hawkins, Lyndah Dreiling, Bruce D. Cheson, Andre K. D. Liem, Rosemary E. Mclntyre, Esteban Abella-Dominicis, Gene Brian Saylors, Joyce He, Jonathan W. Friedberg, Adarsh Joshi
Publikováno v:
Blood. 127(20)
Although agents targeting B-cell receptor signaling have provided practice-changing results in relapsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged administration and provide incomplete responses. Given s
Autor:
Jing Hu, Christopher A. Yasenchak, Leonard M. Klein, Anita Reddy, Jing He, Jeff P. Sharman, Julie A. Di Paolo, Steve Abella, Clarence Eng, Michael Boxer, Kathryn S. Kolibaba
Publikováno v:
Blood. 126:4152-4152
Background: Spleen tyrosine kinase (Syk) is a mediator of B-cell receptor signaling in normal and transformed B-cells. GS-9973 is an orally bioavailable, selective inhibitor of Syk. Methods: This Phase 2 trial enrolled 41 patients with CLL and 15 pat
Autor:
Ori Yellin, Julie A. Di Paolo, Michael J. Hawkins, Feng Jin, Srinivasan Ramanathan, Lixin Shao
Publikováno v:
Cancer Research. 73:26-26
Background: GS-9973 is a selective, reversible, small molecule spleen tyrosine kinase (Syk) inhibitor. GS-1101 is a potent and selective PI3Kδ inhibitor currently in Phase 3 studies. The safety, pharmacokinetics (PK), pharmacodynamics (PD) of GS-997